VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
Globe Newswire (Fri, 4-Sep 7:00 AM ET)
Globe Newswire (Mon, 24-Aug 7:00 AM ET)
Globe Newswire (Wed, 29-Jul 7:00 AM ET)
Globe Newswire (Mon, 27-Jul 7:00 AM ET)
Globe Newswire (Fri, 24-Jul 4:05 PM ET)
Globe Newswire (Thu, 23-Jul 7:00 AM ET)
VERAXA Biotech Announces Regulatory Progress with its BiTAC-TCE Development Plan
Globe Newswire (Mon, 20-Jul 7:00 AM ET)
Globe Newswire (Mon, 13-Jul 7:00 AM ET)
Globe Newswire (Fri, 10-Jul 4:05 PM ET)
Globe Newswire (Mon, 6-Jul 7:00 AM ET)
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
Veraxa Biotech Holding trades on the NASDAQ stock market under the symbol VRXA.
As of October 5, 2026, VRXA stock price climbed to $1.15 with 126,936 million shares trading.
VRXA has a beta of 3.52, meaning it tends to be more sensitive to market movements. VRXA has a correlation of 0.02 to the broad based SPY ETF.
VRXA has a market cap of $162.62 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that VRXA belongs to (by Net Assets): ONEQ.
VRXA support price is $1.06 and resistance is $1.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRXA shares will trade within this expected range on the day.
